SHYNDEC's holding subsidiary signs the "Drug Marketing Authorization Transfer Agreement"
SHYNDEC's subsidiary Guoyao Zhijun Ping Shan signed a "Drug Marketing Authorization Transfer Agreement" with Anhui Meilai, transferring the marketing authorization for Lactulose Oral Solution (15ml:10g) for a transfer fee of 5.86 million yuan. This move aims to enrich the company's product pipeline, enhance market competitiveness, and aligns with the company's medium to long-term development strategy. This matter has no significant impact on the company's current operating performance
According to the announcement from China National Pharmaceutical Group Modern (600420.SH), in order to implement the company's medium and long-term development strategy and enrich the company's product pipeline, its controlling subsidiary, China National Pharmaceutical Zhijun Pingshan, has signed a "Drug Marketing Authorization Transfer Agreement" with Anhui Meilai. Anhui Meilai will transfer the marketing authorization for its product Lactulose Oral Solution (15ml:10g) to China National Pharmaceutical Zhijun Pingshan, with a total transfer fee of RMB 5.86 million.
Lactulose is an osmotic laxative primarily used to treat chronic functional constipation. It also has a prebiotic effect, helping to regulate the balance of intestinal flora, and is used to treat and prevent hepatic encephalopathy in patients experiencing hepatic coma or pre-coma states. The transfer of the marketing authorization for Lactulose Oral Solution (15ml:10g) to China National Pharmaceutical Zhijun Pingshan aligns with the company's strategic development plan, helps to enrich the company's chronic disease treatment product line, and enhances the market competitiveness of China National Pharmaceutical Zhijun Pingshan. This matter will not have a significant impact on the company's current operating performance
